CEL
GOODCeladon Pharmaceuticals Secures £1.0 Million in New Funding
The pharmaceutical company has secured £1.0 million in new funding, providing capital to support its operations and growth.
Celadon Pharmaceuticals
13.40GBX
16.52%
Market Cap
9.23M
Volume
785.49k
483% of avg
P/E Ratio
EPS (TTM)
Beta
-0.11
Day Range
0.00p - 0.00p
52 Week Range
0.00p13.40p80.00p
13.40p
Upcoming Events
CEL
NEUTRALCeladon Pharmaceuticals Secures Additional Funding, Delays Annual Report
The pharmaceutical company has secured additional debt funding and is in talks for a potential future investment, but has delayed publishing its annual report.
CEL
GOODCeladon Pharmaceuticals Secures New £0.5 Million Credit Facility
The pharmaceutical company has secured a new £0.5 million credit facility to support its operations, providing additional funding as it continues to engage with other finance providers.
CEL
NEUTRALCeladon Pharmaceuticals Provides Funding Update, Announces AGM
The pharmaceutical company has provided an update on its financial position and announced the date of its upcoming Annual General Meeting.
CEL
BADCeladon Pharmaceuticals Seeks New Funding to Continue Operations
The pharmaceutical company is seeking new funding to continue operations, as it has limited working capital and its ability to trade is dependent on securing additional financing.
CEL
BADCeladon Pharmaceuticals Seeks Urgent Funding to Avoid Administration
The pharmaceutical company is urgently seeking additional funding to avoid being placed into administration, as it has limited working capital and is yet to receive requested funds from its credit facility.
CEL
NEUTRALCeladon Pharmaceuticals Terminates Credit Facility
The pharmaceutical company has decided to terminate a credit facility it had previously announced, citing no longer needing the funds.
CEL
BADCeladon Pharmaceuticals Faces Funding Crisis as Credit Facilities Remain Unavailable
The pharmaceutical company is facing a funding crisis, with uncertainty around securing additional financing to continue operations.
CEL
VERY BADCeladon Pharmaceuticals Plc Proposes Delisting from AIM
The pharmaceutical company plans to delist from the AIM market, citing a desire to reduce costs and access capital more easily as an unlisted firm. However, the move raises concerns over governance and shareholder value.
CEL
NEUTRALCeladon Pharmaceuticals Faces Funding Delay
The pharmaceutical company faces a delay in receiving new funding, but is taking steps to ensure it has sufficient working capital.